251 related articles for article (PubMed ID: 27020861)
1. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.
Daurio NA; Tuttle SW; Worth AJ; Song EY; Davis JM; Snyder NW; Blair IA; Koumenis C
Cancer Res; 2016 Jun; 76(11):3295-306. PubMed ID: 27020861
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
4. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.
Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV
Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952
[TBL] [Abstract][Full Text] [Related]
6. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway.
Wu ST; Sun GH; Cha TL; Kao CC; Chang SY; Kuo SC; Way TD
J Biomed Sci; 2016 Aug; 23(1):60. PubMed ID: 27526942
[TBL] [Abstract][Full Text] [Related]
7. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
9. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
[TBL] [Abstract][Full Text] [Related]
10. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
11. Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells.
Yu H; Zhang H; Dong M; Wu Z; Shen Z; Xie Y; Kong Z; Dai X; Xu B
Int J Oncol; 2017 Jan; 50(1):161-172. PubMed ID: 27922662
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
13. Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade.
Rivera Rivera A; Castillo-Pichardo L; Gerena Y; Dharmawardhane S
PLoS One; 2016; 11(6):e0157251. PubMed ID: 27285995
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway.
Liu Y; Tong L; Luo Y; Li X; Chen G; Wang Y
J Cell Biochem; 2018 Jul; 119(7):6162-6172. PubMed ID: 29663499
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
17. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
18. Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells.
Qi W; Sun M; Kong X; Li Y; Wang X; Lv S; Ding X; Gao S; Cun J; Cai C; Wang X; Chen J; Yin A; Yang Q
Oncotarget; 2016 May; 7(18):26003-15. PubMed ID: 27027343
[TBL] [Abstract][Full Text] [Related]
19. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
[TBL] [Abstract][Full Text] [Related]
20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
